Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Differential expression of the lncRNA MIR17HG and miR-18a/miR-20a as candidate ncRNA signatures in stage II/III breast cancer and bioinformatic analysis of ncRNA–mRNA regulatory axes

Articles in Press

Document Type : Original Article

Authors
Reyhane Alidousti Shahraki 1
Sara Tavallaei 2
Afsaneh Malekzadeh Shafaroudi 3
saba Abbassioun 1
Nahid Nafissi 4
Seyed-Javad Mowla 1
1 Molecular Genetics Department, Biological Sciences Faculty, Tarbiat Modares University, Tehran, Iran
2 Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
3 Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
4 Rasoul Akram Hospital Clinical Research and Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran
10.22038/ijbms.2026.95193.20529
Abstract
Objective(s): Breast cancer has remained a significant cause of mortality associated with cancer, necessitating a deeper molecular understanding to improve diagnostics and targeted therapies. Noncoding RNAs (ncRNAs) and their regulatory ncRNA–mRNA axes have recently emerged as important modulators of cancer progression and potential tools for earlier detection and more precise stratification of breast cancer. Among them, MIR17HG variants and the precise regulatory axes of miR-18a/miR-20a, and their mechanisms in stage II/III BC, remain elusive.
Materials and Methods: This study addresses this critical gap by integrating data from TCGA miRNAseq and RNAseq datasets with experimental qRT-PCR validation on patient tissues. We investigate MIR17HG transcript variants and their associated miRNAs, especially miR-18a and miR-20a, as candidate stage-associated molecules in stage II/III breast cancer. Co-expressed mRNAs were identified through gene co-expression networks (WGCNA).
Results: Potential MIR17HG–miR-18a/20a-mRNA regulatory axes were computationally predicted and functionally annotated to elucidate their involvement in cancer-related signaling pathways. Our findings showed that both MIR17HG splice variants were down-regulated, while their associated miRNAs (miR-18a-5p and miR-20a-5p) were overexpressed. Based on in silico prediction and functional annotation, we propose three candidate MIR17HG-centred axes: MIR17HG–miR-20a–BTG3 (linked to RNA degradation), MIR17HG–miR-18a/miR-20a–PARD6B (Hippo signaling and cell polarity), and MIR17HG–miR-20a–ZNF367 (endocytosis-related processes).
Conclusion: Together, these data support MIR17HG and its associated miRNAs as candidate stage II/III breast cancer–associated ncRNA signatures and provide a framework for future functional and clinical validation studies.
Keywords
Breast cancer
Endocytosis
Hippo signaling pathway
Long non-coding RNA
MIR17HG
MicroRNAs
Noncoding RNA
RNA degradation
Subjects
1. Booker R. A brief report on the 2020 Canadian Global Oncology Workshop. Can Oncol Nurs J 2021;31:345–346. 
2. Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 2025;1–9. 
3. McGuire A. Factors influencing diagnosis and outcome in HER2 receptor. Cancer Metastasis Rev 2015;34:145–155. 
4. Amaral PP, Mattick JS. Noncoding RNA in development. Mamm Genome  2008;19:454–92. 
5. Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol 2009;21:416–425. 
6. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. Physiol Rev 2016; 96:1297-1325.
7. Shi J, Zhou T, Chen Q. Exploring the expanding universe of small RNAs. Nat Cell Biol 2022;24:415–423. 
8. Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis 2017;38:485–491. 
9. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861–874. 
10.    Gholipour A, Shakerian F, Zahedmehr A, Irani S, Malakootian M, Mowla SJ. Bioinformatics analysis to find novel biomarkers for coronary heart disease. Iran J Public Health 2022;51:1152. 
11.    Olive V, Li Q, He L. mir‐17‐92: A polycistronic oncomir with pleiotropic functions. Immunol Rev 2013;253:158–166. 
12.    Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217–222. 
13.    Li H, Wu Q, Li T, Liu C, Xue L, Ding J, et al. The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: Evidence and literature review. Oncotarget 2017;8:45060. 
14.    Zhang X, Li Y, Qi P, Ma Z. Biology of MiR-17-92 cluster and its progress in lung cancer. Int J Med Sci 2018;15:1443. 
15.    Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:1–13. 
16.    Chen Y, Wang X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res 2020;48:D127–D-131. 
17.    Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol 2019;20:1–10. 
18.    Das G, Das T, Parida S, Ghosh Z. LncRTPred: Predicting RNA–RNA mode of interaction mediated by lncRNA. IUBMB Life 2024;76:53–68. 
19.    Tastsoglou S, Skoufos G, Miliotis M, Karagkouni D, Koutsoukos I, Karavangeli A, et al. DIANA-miRPath v4. 0: Expanding target-based miRNA functional analysis in cell-type and tissue contexts. Nucleic Acids Res 2023;51:W154–W159. 
20.    Tastsoglou S, Alexiou A, Karagkouni D, Skoufos G, Zacharopoulou E, Hatzigeorgiou AG. DIANA-microT 2023: Including predicted targets of virally encoded miRNAs. Nucleic Acids Res 2023;51:W148–W153. 
21.    Karagkouni D, Paraskevopoulou MD, Tastsoglou S, Skoufos G, Karavangeli A, Pierros V, et al. DIANA-LncBase v3: Indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res 2020;48:D101–D110. 
22.    Paraskevopoulou MD, Karagkouni D, Vlachos IS, Tastsoglou S, Hatzigeorgiou AG. MicroCLIP super learning framework uncovers functional transcriptome-wide miRNA interactions. Nat Commun 2018;9:3601. 
23.    Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase v2. 0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 2014;42:D92–D97. 
24.    Lu Y, Thomson JM, Wong HYF, Hammond SM, Hogan BLM. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 2007;310:442–453. 
25.    Xu J, Hu M, Gao Y, Wang Y, Yuan X, Yang Y, et al. LncRNA MIR17HG suppresses breast cancer proliferation and migration as ceRNA to target FAM135A by sponging miR-454-3p. Mol Biotechnol 2023;65:2071–2085. 
26.    Hossain MM, Sultana A, Barua D, Islam MN, Gupta A, Gupta S. Differential expression, function and prognostic value of miR-17–92 cluster in ER-positive and triple-negative breast cancer. Cancer Treat Res Commun 2020;25:100224. 
27.    Yuan G, Liu B, Han W, Zhao D. LncRNA-MIR17HG mediated upregulation of miR-17 and miR-18a promotes colon cancer  progression via activating Wnt/β-catenin signaling. Transl Cancer Res 2019 Aug;8:1097–1108. 
28.    Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013;20:1603–1614. 
29.    Mihailovich M, Bremang M, Spadotto V, Musiani D, Vitale E, Varano G, et al. MiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell  lymphoma growth. Nat Commun 2015;6:8725. 
30.    Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004;64:3087–3095. 
31.    Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007;117:2059–2066. 
32.    Chacon-Cortes D, Smith RA, Lea RA, Youl PH, Griffiths LR. Association of microRNA 17–92 cluster host gene (MIR17HG) polymorphisms with breast cancer. Tumor Biol 2015;36:5369–5376. 
33.    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LTR. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study. J Transl Med 2019;17:1–20. 
34.    Kolenda T, Guglas K, Kopczyńska M, Sobocińska J, Teresiak A, Bliźniak R, et al. Good or not good: Role of miR-18a in cancer biology. Reports Pract Oncol Radiother 2020;25:808–819. 
35.    Shen K, Cao Z, Zhu R, You L, Zhang T. The dual functional role of MicroRNA-18a (miR-18a) in cancer development. Clin Transl Med 2019;8:32. 
36.    Calvano Filho CMC, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, et al. Triple-negative and luminal A breast tumors: Differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumor Biol 2014;35:7733–7741. 
37.    Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, et al. A phase I/IIa trial using CD19-targeted third-generation car T cells for lymphoma  and leukemia. Clin Cancer Res 2018;24:6185–6194. 
38.    He Y, Ma H, Wang J, Kang Y, Xue Q. miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1. Oncol Lett 2021;21:427. 
39.    Guo L, Zhu Y, Li L, Zhou S, Yin G, Yu G, et al. Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and  differentiation of osteoclasts by targeting SRCIN1. Cancer Med 2019;8:5687–5701. 
40.    Stoen MJ, Andersen S, Rakaee M, Pedersen MI, Ingebriktsen LM, Donnem T, et al. Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative  Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study. Cancers (Basel) 2021;13:4096. 
41.    Pickering MT, Stadler BM, Kowalik TF. MiR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 2009;28:140–145. 
42.    Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060–1065. 
43.    Li JY, Zhang Y, Zhang WH, Jia S, Kang Y, Zhu XY. Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pacific J Cancer Prev 2012;13:1901–1906. 
44.    Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, et al. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in  basal breast cancers. Breast Cancer Res 2014;16:R78. 
45.    Deng M, Wang X, Xiong Z, Tang P. Control of RNA degradation in cell fate decision. Front cell Dev Biol 2023;11:1164546. 
46.    Nogueira G, Fernandes R, García-Moreno JF, Romão L. Nonsense-mediated RNA decay and its bipolar function in cancer. Mol Cancer 2021;20:72. 
47.    O’Malley S, Su H, Zhang T, Ng C, Ge H, Tang CK. TOB suppresses breast cancer tumorigenesis. Int J Cancer 2009;125:1805–1813. 
48.    Ezzeddine N, Chang TC, Zhu W, Yamashita A, Chen CYA, Zhong Z, et al. Human TOB, an antiproliferative transcription factor, is a poly (A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol 2007;27:7791–7801. 
49.    Ezzeddine N, Chen CYA, Shyu AB. Evidence providing new insights into TOB-promoted deadenylation and supporting a link between TOB’s deadenylation-enhancing and antiproliferative activities. Mol Cell Biol 2012;32:1089–1098. 
50.    Gou W feng, Yang X feng, Shen D fu, Zhao S, Liu Y peng, Sun H zhi, et al. The roles of BTG3 expression in gastric cancer: A potential marker for  carcinogenesis and a target molecule for gene therapy. Oncotarget 2015;6:19841–19867. 
51.    Yanagida S, Taniue K, Sugimasa H, Nasu E, Takeda Y, Kobayashi M, et al. ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian  carcinoma. Sci Rep 2013;3:1305. 
52.    Karasek C, Ashry M, Driscoll CS, Knott JG. A tale of two cell-fates: Role of the hippo signaling pathway and transcription factors in early lineage formation in mouse preimplantation embryos. Mol Hum Reprod 2020;26:653–664. 
53.    Ahmed SM, Macara IG. Mechanisms of polarity protein expression control. Curr Opin Cell Biol 2016;42:38–45. 
54.    Yang H, Yang J, Zheng X, Chen T, Zhang R, Chen R, et al. The hippo pathway in breast cancer: The extracellular matrix and hypoxia. Int J Mol Sci 2024;25:12868. 
55.    Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, et al. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 2008;68:8201–8209. 
56.    Muthuswamy SK, Xue B. Cell polarity as a regulator of cancer cell behavior plasticity. Annu Rev Cell Dev Biol 2012;28:599–625. 
57.    Gupta SRR, Nagar G, Mittal P, Rana S, Singh H, Singh R, et al. Breast cancer therapeutics and hippo signaling pathway: Novel microRNA-gene-protein interaction networks. Omi A J Integr Biol 2023;27:273–280. 
58.    Sadri F, fatemeh Hosseini S, Rezaei Z, Fereidouni M. Hippo-YAP/TAZ signaling in breast cancer: Reciprocal regulation of microRNAs and implications in precision medicine. Genes Dis 2024;11:760–771. 
59.    Cunliffe HE, Jiang Y, Fornace KM, Yang F, Meltzer PS. PAR6B is required for tight junction formation and activated PKCζ localization in breast cancer. Am J Cancer Res 2012;2:478. 
60.    Marques E, Englund JI, Tervonen TA, Virkunen E, Laakso M, Myllynen M, et al. Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers. Oncogene 2016;35:1386–1398. 
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 12 September 2026